Oxonic acid potassium salt
(Synonyms: 氧嗪酸钾; Potassium azaorotate; Potassium otastat) 目录号 : GC17025
Oxonic acid potassium salt能够选择性地、竞争性地抑制尿酸酶的活性，能有效导致体内尿酸水平升高。Oxonic acid potassium salt抑制5-氟尿嘧啶（5-FU）磷酸化为5-氟尿苷-5'-单磷酸酯的过程。
Cas No.:2207-75-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Oxonic acid potassium salt selectively and competitively inhibits the activity of uricase, effectively elevating uric acid levels in vivo. Oxonic acid potassium salt inhibits the phosphorylation of 5-fluorouracil (5-FU) to 5-fluorouridine-5'-monophosphate[1-2]. Oxonic acid potassium salt can be used to establish animal models of hyperuricemia and serves as an auxiliary tool in cancer research[3-4].
In vivo, treatment of Kunming mice with Oxonic acid potassium salt (350mg/kg/day) combined with Hypoxanthine (450mg/kg/day) via intraperitoneal injection and oral gavage for 8 consecutive weeks induced a chronic hyperuricemia model, Oxonic acid potassium salt significantly led to left ventricular anterior wall thickening, myocardial structural disorganization, increased cardiac mass, and was accompanied by complications such as renal enlargement and renal tubule dilation[5]. Treatment of Kunming mice with Oxonic acid potassium salt (350mg/kg/day) combined with Hypoxanthine (450mg/kg/day) via intraperitoneal injection and oral gavage for 1 consecutive week induced a hyperuricemia model, Oxonic acid potassium salt significantly decrease in polyamine levels in cardiomyocytes and upregulation of the protein expression of the key polyamine synthesis enzyme ODC1 and the metabolic enzyme SAT1, leading to cardiomyocyte injury[6].
References:
[1] Zhang N, Zhang B, Chen X, et al. Effects and mechanisms of Polygonati Rhizoma polysaccharide on potassium oxonate and hypoxanthine-induced hyperuricemia in mice. Int J Biol Macromol. 2024 Sep 13;280(Pt 1):135550.
[2] Yamashita T, Ueda Y, Fuji N, et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol. 2006 Aug;58(2):183-8.
[3] Tian J, Wang B, Xie B, et al. Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. Mod Rheumatol. 2022 Jan 5;32(1):221-230.
[4] Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Pharmacol. 2000;46(1):51-6.
[5] Lin C, Zheng Q, Li Y, et al. Assessment of the influence on left ventricle by potassium oxonate and hypoxanthine-induced chronic hyperuricemia. Exp Biol Med (Maywood). 2023 Jan;248(2):165-174.
[6] Lin C, Zheng Q, Yu H, et al. Uric acid-induced cardiomyocytic polyamines' insufficience: a potential mechanism mediates cardiomyocytic injury. Front Endocrinol (Lausanne). 2025 Apr 7;16:1504614.
Oxonic acid potassium salt能够选择性地、竞争性地抑制尿酸酶的活性，能有效导致体内尿酸水平升高。Oxonic acid potassium salt抑制5-氟尿嘧啶（5-FU）磷酸化为5-氟尿苷-5'-单磷酸酯的过程[1-2]。Oxonic acid potassium salt可用构建高尿酸血症动物模型，和作为肿瘤研究的辅助工具[3-4]。
在体内，Oxonic acid potassium salt（350mg/kg/天）联合Hypoxanthine（450mg/kg/天）腹腔注射及灌胃处理昆明小鼠（连续8周），Oxonic acid potassium salt诱导的慢性高尿酸血症模型显著引起左心室前壁增厚、心肌结构紊乱及心脏质量增加，并伴随肾脏肿大、肾小管扩张等并发症[5]。Oxonic acid potassium salt（350mg/kg/天）联合Hypoxanthine（450mg/kg/天）腹腔注射及灌胃处理昆明小鼠（连续1周），Oxonic acid potassium salt诱导的高尿酸血症模型导致心肌细胞内多胺水平显著降低，并上调多胺合成关键酶ODC1和代谢酶SAT1的蛋白表达，导致心肌细胞损伤[6]。
| Animal experiment [1]: | |
Animal models | Kunming (KM) mice |
Preparation Method | Mice were intraperitoneally administered Oxonic acid potassium salt (350mg/kg/day) combined with oral hypoxanthine (450mg/kg/day) for 8 weeks. Cardiac function and histopathology were assessed post-treatment. |
Dosage form | 350mg/kg/day; i.p; Daily administration for 8 weeks. |
Applications | Oxonic acid potassium salt and hypoxanthine co-administration induced chronic hyperuricemia, leading to left ventricular remodeling characterized by anterior wall thickening, myocardial disorganization, inflammatory infiltration, and collagen fibrosis. |
References: | |
| Cas No. | 2207-75-2 | SDF | |
| 别名 | 氧嗪酸钾; Potassium azaorotate; Potassium otastat | ||
| 化学名 | potassium;4,6-dioxo-1H-1,3,5-triazine-2-carboxylate | ||
| Canonical SMILES | C1(=NC(=O)NC(=O)N1)C(=O)[O-].[K+] | ||
| 分子式 | C4H2KN3O4 | 分子量 | 195.17 |
| 溶解度 | ≥ 19.5mg/mL in Water with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.1237 mL | 25.6187 mL | 51.2374 mL |
| 5 mM | 1.0247 mL | 5.1237 mL | 10.2475 mL |
| 10 mM | 512.4 μL | 2.5619 mL | 5.1237 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet